UBS sets USD 92.00 target for BridgeBio Pharma stock
Published on 10/15/2026 at 18:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and quarterly date
- UBS set a USD 92.00 target and Buy rating for BridgeBio Pharma on October 14, 2026.
- BridgeBio reported USD 243.68 million in second-quarter revenue on August 10, 2026.
- BridgeBio Pharma stock costs EUR 59.91 at Lang & Schwarz on October 15, 2026 at 6:44 p.m. CEST.
- BridgeBio Pharma is scheduled to report quarterly results on October 28, 2026.
UBS initiated coverage of BridgeBio Pharma with a Buy rating and a USD 92.00 price target on October 14, 2026, according to Markets Insider. Against the USD 67.22 Nasdaq quote on October 15, 2026, the target stands 36.86 percent higher. BridgeBio Pharma stock was at EUR 59.91 at Lang & Schwarz on October 15, 2026 at 6:44 p.m. CEST.
Revenue growth sets the operating backdrop
BridgeBio reported USD 243.68 million in revenue for the second quarter ended June 30, 2026, compared with USD 110.57 million a year earlier. The figures, including a GAAP net loss of USD 152.22 million versus USD 181.90 million in the prior-year quarter, were reported by Markets Insider.
Stock sits below the yearly high
The Nasdaq quote was USD 67.22 at 12:54 p.m. ET on October 15, 2026. BridgeBio Pharma's 52-week range was USD 52.75 to USD 93.42, placing the stock 28.04 percent below its high. Trading volume stood at 889,390 shares against an average of 2,399,192 shares.
Valuation and reporting date
BridgeBio Pharma had a market capitalization of USD 13.2 billion on October 15, 2026. Its next quarterly results are scheduled for October 28, 2026, according to GetSignal. The date gives investors the next formal checkpoint for revenue, earnings and commercial progress.
Comparison with peers
BridgeBio Pharma (Nasdaq, USD): P/E -18.76, market capitalization USD 13.2 billion
Alnylam Pharmaceuticals (Nasdaq, USD): daily change plus 3.85 percent, P/E 39.40, market capitalization USD 31.2 billion
Ionis Pharmaceuticals (Nasdaq, USD): daily change plus 3.10 percent, P/E -12.73, market capitalization USD 7.3 billion
Price remains the market frame
The euro quotation places BridgeBio Pharma below its dollar-denominated yearly high, while the UBS target provides a separate analyst benchmark in the primary trading currency. The company combines commercial revenue growth with continued reported losses, making the October results date the next scheduled test for the investment case.
BridgeBio Pharma stock was trading at EUR 59.91 at Lang & Schwarz on October 15, 2026 at 6:44 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of BridgeBio Pharma stock.
BridgeBio Pharma stock data
- Company: BridgeBio Pharma, Inc.
- ISIN: US10806X1028
- WKN: A2PLX7
- Ticker: BBIO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 6:44 p.m. CEST): EUR 59.91
- Market capitalization: USD 13.2 billion (as of October 15, 2026)
- 52-week range: USD 52.75-USD 93.42 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
